International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Development of the OncoSignal Algorithm for Detecting Low Abundance Circulating Tumor DNA Signals Compared with Conventional Threshold Based and Machine Learning Detection

Article Information

Volume / Issue3 / 1 (January-March 2022)
Pages87-103
AccessOpen Access

Publication Timeline

  • Received05 February 2022
  • Accepted03 March 2022

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Circulating tumor DNA (ctDNA) provides a minimally invasive molecular signal for cancer detection, residual disease assessment, treatment-response monitoring, and recurrence surveillance; however, reliable identification becomes difficult when tumor-derived fragments occur at very low variant allele fractions within a dominant background of normal cell-free DNA. This study develops OncoSignal, a novel computational algorithm for detecting low-abundance ctDNA through integrated background-error modelling, fragment-level signal weighting, molecular-context encoding, adaptive denoising, probabilistic evidence fusion, and confidence-calibrated classification. Unlike conventional fixed-threshold approaches that classify candidate variants primarily according to read depth, allele frequency, or predefined quality cut-offs, OncoSignal constructs a multidimensional evidence score from variant allele frequency, base quality, mapping quality, strand consistency, fragment length, genomic context, local sequencing error, molecular support, and locus-specific noise characteristics. The proposed architecture incorporates an Adaptive Molecular Noise Suppression module, Fragment-Context Attention Network, Bayesian Evidence Fusion layer, and Dynamic Signal Decision Boundary, allowing the detection threshold to adjust to sequencing depth, background error distribution, and sample-specific noise. OncoSignal is designed for comparative benchmarking against conventional variant allele frequency thresholding, statistical binomial detection, logistic regression, support vector machine, random forest, XGBoost, multilayer perceptron, one-dimensional convolutional neural networks, long short-term memory networks, and Transformer-based classifiers. Performance is evaluated across progressively decreasing ctDNA fractions using sensitivity, specificity, precision, F1-score, Matthews correlation coefficient, area under the receiver operating characteristic curve, area under the precision-recall curve, false-positive rate, calibration error, signal-to-noise ratio, and limit of detection. Particular emphasis is placed on the clinically demanding low-abundance interval below 1% variant allele frequency and the ultra-low range below 0.1%. Comparative graphical analysis includes ROC and precision-recall curves, sensitivity-versus-variant-allele-frequency profiles, three-dimensional surfaces relating sequencing depth, tumor fraction, and detection probability, calibration plots, signal-to-noise distributions, and error-rate comparisons across algorithms. The central hypothesis is that adaptive integration of molecular evidence and locus-specific background modelling will preserve true weak tumor signals while suppressing sequencing artefacts more effectively than fixed thresholds and conventional machine-learning classifiers. The resulting OncoSignal framework is intended to provide a more sensitive, specific, interpretable, and technically robust computational platform for low-abundance ctDNA detection and subsequent liquid-biopsy applications.

References

  1. Atalor SI. Data-driven cheminformatics models for predicting bioactivity of natural compounds in oncology. Int J Sci Res Mod Technol. 2022;1(1):65-76. doi:10.38124/ijsrmt.v1i1.496. [Google Scholar][Crossref]
  2. Nwokocha CR, Peter-Anyebe AC, Ijiga OM. Evaluating FHIR-driven interoperability frameworks for secure system migration and data exchange in U.S. health information networks. Int J Sci Res Sci Technol. 2021. doi:10.32628/IJSRST523105135. [Google Scholar][Crossref]
  3. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223-238. doi:10.1038/nrc.2017.7. [Google Scholar][Crossref]
  4. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:44 6-451. doi:10.1038/nature22364. [Google Scholar][Crossref]
  5. ames UU. Machine learning-driven anomaly detection for supply chain integrity in 5G industrial automation systems. Int J Sci Res Sci Eng Technol. 2022;9(2). doi:10.32628/IJSRSET22549. [Google Scholar][Crossref]
  6. Idika CN, Salami EO, Ijiga OM, Enyejo LA. Deep learning driven malware classification for cloud-native microservices in edge computing architectures. Int J Sci Res Comput Sci Eng Inf Technol. 2021;7(4). doi:10.32628/CSEIT182551. [Google Scholar][Crossref]
  7. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403). doi:10.1126/scitranslmed.aan2415. [Google Scholar][Crossref]
  8. Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114-1124. doi:10.1038/s41591-020-0915-3. [Google Scholar][Crossref]
  9. Amebleh J, Igba E, Ijiga OM. Graph-based fraud detection in open-loop gift cards: heterogeneous GNNs, streaming feature stores, and near-zero-lag anomaly alerts. Int J Sci Res Sci Eng Technol. 2021;8(6). doi:10.32628/IJSRSET214418. [Google Scholar][Crossref]
  10. Idika CN. Lightweight authentication mechanisms for securing wearable medical devices in body area networks. Glob J Multidiscip Stud. 2022;11(9). doi:10.5281/zenodo.17519630. [Google Scholar][Crossref]
  11. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547-555. doi:10.1038/nbt.3520. [Google Scholar][Crossref]
  12. Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25:1928-1937. doi:10.1038/s41591-019-0652-7. [Google Scholar][Crossref]
  13. Atalor SI. Federated learning architectures for predicting adverse drug events in oncology without compromising patient privacy. ICONIC Res Eng J. 2019;2(12). [Google Scholar][Crossref]
  14. Kwarteng RA, Idoko IP, Ijiga OM, Enyejo LA. Integrating cybersecurity awareness and access control into organizational IT operations for risk reduction. Int J Sci Res Comput Sci Eng Inf Technol. 2020;6(1):243-261. doi:10.32628/CSEIT23906128. [Google Scholar][Crossref]
  15. Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466). doi:10.1126/scitranslmed.aat4921. [Google Scholar][Crossref]
  16. Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39:1537 -1547. doi:10.1038/s41587-021-00981-w. [Google Scholar][Crossref]
  17. Ijiga OM, Anim-Sampong SD, Ilesanmi MO. Land use optimization for utility-scale solar and wind projects: integrating estate management and technology-driven site analytics. Int J Sci Res Sci Eng Technol. 2022;9(6):505-510. doi:10.32628/IJSRSET25122274. [Google Scholar][Crossref]
  18. Ijiga OM, Ifenatuora GP, Olateju M. Digital storytelling as a tool for enhancing STEM engagement: a multimedia approach to science communication in K-12 education. Int J Multidiscip Res Growth Eval. 2021;2(5):495-505. doi:10.54660/IJMRGE.2021.2.5.495-505. [Google Scholar][Crossref]
  19. Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570:385-389. doi:10.1038/s41586-019-1272-6. [Google Scholar][Crossref]
  20. Chabon JJ, Hamilton EG, Kurtz DM, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580:245 -251. doi:10.1038/s41586-020-2140-0. [Google Scholar][Crossref]
  21. Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021;372(6538). doi:10.1126/science.aaw3616. [Google Scholar][Crossref]
  22. Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928-1937. doi:10.1038/s41591-019-0652-7. [Google Scholar][Crossref]
  23. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547 -555. doi:10.1038/nbt.3520. [Google Scholar][Crossref]
  24. Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114 -1124. doi:10.1038/s41591-020-0915-3. [Google Scholar][Crossref]
  25. Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, et al. Detection and characterization of International Journal of Medical and All Body Health Research www.allmedicaljournal.com lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12:5060. doi:10.1038/s41467-021-24994-w. [Google Scholar][Crossref]
  26. Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563(7732):579-583. doi:10.1038/s41586-018-0703-0. [Google Scholar][Crossref]
  27. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164(1-2):57-68. doi:10.1016/j.cell.2015.11.050. [Google Scholar][Crossref]
  28. Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet. 2016;48(10):1273-1278. doi:10.1038/ng.3648. [Google Scholar][Crossref]
  29. Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548 -554. doi:10.1038/nm.3519. [Google Scholar][Crossref]
  30. Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324. doi:10.1038/s41467-017-00965-y. [Google Scholar][Crossref]
  31. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547-555. doi:10.1038/nbt.3520. [Google Scholar][Crossref]
  32. Mathios D, Johansen JS, Cristiano S, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12:5060. doi:10.1038/s41467-021-24994-w. [Google Scholar][Crossref]
  33. Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114-1124. doi:10.1038/s41591-020-0915-3. [Google Scholar][Crossref]

How to Cite

Oni, R. O., & Adeyeye, Y. I. (2022). Development of the OncoSignal Algorithm for Detecting Low Abundance Circulating Tumor DNA Signals Compared with Conventional Threshold Based and Machine Learning Detection. International Journal of Medical and All Body Health Research, 3(1), 87-103. https://doi.org/10.54660/IJMBHR.2022.3.1.87-103

Oni, Rukayat Olayemi, and Yewande Iyimide Adeyeye. "Development of the OncoSignal Algorithm for Detecting Low Abundance Circulating Tumor DNA Signals Compared with Conventional Threshold Based and Machine Learning Detection." International Journal of Medical and All Body Health Research, vol. 3, no. 1, 2022, pp. 87-103. https://doi.org/10.54660/IJMBHR.2022.3.1.87-103.

Oni, R. O. and Adeyeye, Y. I. (2022) 'Development of the OncoSignal Algorithm for Detecting Low Abundance Circulating Tumor DNA Signals Compared with Conventional Threshold Based and Machine Learning Detection', International Journal of Medical and All Body Health Research, 3(1), pp. 87-103. doi: 10.54660/IJMBHR.2022.3.1.87-103.

Oni RO, Adeyeye YI. Development of the OncoSignal Algorithm for Detecting Low Abundance Circulating Tumor DNA Signals Compared with Conventional Threshold Based and Machine Learning Detection. International Journal of Medical and All Body Health Research. 2022;3(1):87-103. doi:10.54660/IJMBHR.2022.3.1.87-103

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASE

A newly published article may take a few days to appear on these services.